← Back to Search

Other

CX-904 for Advanced Solid Cancers

Phase 1
Recruiting
Research Sponsored by CytomX Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with brain metastases that are ≤ 1 cm, are symptomatic, and require treatment may be eligible after discussion with Medical Monitor.
Eastern Cooperative Oncology Group performance status of 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights

Study Summary

This trial is testing a new drug, CX-904, to see if it is safe and effective in treating adults with metastatic or locally advanced unresectable solid tumors.

Who is the study for?
This trial is for adults with advanced solid tumors that can't be surgically removed and have spread. They should have tried standard treatments already, not have serious heart issues or autoimmune diseases, and agree to use effective birth control. Those with small, symptom-free brain metastases may join after special consideration.Check my eligibility
What is being tested?
The study tests CX-904's safety and effectiveness in treating advanced solid tumors. It will assess how the body processes the drug (PK), its impact on the tumor (PD), tolerability at different doses, and any potential benefits in shrinking or controlling tumor growth.See study design
What are the potential side effects?
Since this is a first-in-human study for CX-904, specific side effects are unknown but could include typical reactions seen with cancer drugs such as nausea, fatigue, allergic reactions, blood count changes, organ inflammation or other unexpected symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have small brain tumors (≤1 cm) that need treatment.
Select...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and I've had standard treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patients Experiencing Dose-limiting Toxicity
Secondary outcome measures
Disease Control Rate (DCR)
Duration of Response (DOR)
Investigator-assessed Progression-Free Survival (PFS)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CX-904Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

CytomX TherapeuticsLead Sponsor
7 Previous Clinical Trials
784 Total Patients Enrolled
Monika Vainorius, M.D.Study DirectorCytomX Therapeutics, Inc
2 Previous Clinical Trials
258 Total Patients Enrolled
Lawrence LuStudy DirectorCytomX Therapeutics, Inc

Media Library

CX-904 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05387265 — Phase 1
Solid Tumors Research Study Groups: CX-904
Solid Tumors Clinical Trial 2023: CX-904 Highlights & Side Effects. Trial Name: NCT05387265 — Phase 1
CX-904 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05387265 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for participants to join this research initiative?

"The clinicaltrials.gov webpage reveals that this experiment is actively seeking participants, having been posted in February of 2022 and subsequently edited in May of the same year."

Answered by AI

How many volunteers are included in this research study?

"Affirmative. Per the information hosted on clinicaltrials.gov, this experiment is currently enrolling patients. It was initially posted in February 22nd 2022 and has recently been amended - as of May 19th 2022 - to incorporate 100 participants across a single site."

Answered by AI
~39 spots leftby Aug 2025